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820-6 Once-Daily Niacin Extended-Release is Effective and 
Safe for Treatment of Dyslipidemia Associated With 
Chronic Kidney Disease
Mark E. McGovern, Carolin M. Malott, Eric J. Stanek, Phillip D. Simmons, Kos Division of 
Medical Affairs, Weston, FL
Background: Low levels of high-density lipoprotein cholesterol (HDL-C) and elevated
triglycerides (TG) and lipoprotein (a) [Lp(a)] are frequently seen in patients with chronic
kidney disease (CKD), who are at 2- to 3-fold elevated risk for coronary heart disease.
Niacin is the most potent drug to raise HDL-C. It also reduces TG and Lp(a). However,
niacin and its metabolites are primarily excreted in urine. We hypothesized that niacin's
lipid effects might be slightly enhanced in patients with CKD.
Methods: This was a retrospective analysis of 458 dyslipidemic patients from an open-
label, multicenter, 48-week study of once-daily extended-release niacin dosed up to 3
grams daily (average dose of 2 grams). We defined CKD as estimated baseline creati-
nine clearance (Cockroft-Gault equation) < 75 mL/min and evaluated lipid efficacy and
safety (liver enzymes, fasting glucose, and myopathy) in these patients.
Results: Compared to patients without CKD (N=282), those with CKD (N=176) were
older (62 versus 50 years), more often female (57% versus 23%), with lower body mass
index (27 versus 30). Mean estimated creatinine clearance (mL/min, + standard error)
was 61+0.7 with CKD versus 93+0.9 without. Lipid results are shown. There were no dif-
ferences between groups in percent of patients with 3-fold increases in liver tests (<1% in
each group) or changes in fasting glucose. No myopathy was reported.
Conclusion: We conclude that once-daily extended-release niacin is effective and safe
for patients with CKD.
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1103-165 Serum Levels of Angiogenic Growth Factors Predict 
Long-Term Clinical Outcome After Percutaneous 
Coronary Revascularization
Karine Sautiere, Sophie Susen, Francois Cuilleret, Akram Chmait, Arnaud Sudre, 
Frederic Mouquet, Jean Dallongeville, Christophe Bauters, Jean Marc Lablanche, Brigitte 
Jude, Eric Van Belle, Hopital Cardiologique, Lille, France
Context : angiogenic growth factors are important in tissue and vascular repair and it has
been suggested that serum levels could reflect the degree of vascular injury in patients
with atherosclerosis. The predictive value of serum levels of angiogenic growth factors in
the context of percutaneous coronary revascularization (PCR) is unclear. Our objective
was to clarify this issue.
Methods: A total of 262 consecutive patients who underwent coronary angioplasty had
blood sample for measurement of CRP, IL6, hepatocyte Results : growth factor (HGF)
and vascular endothelial growth factor (VEGF) levels immediately before PCR. Patients
who underwent primary or rescue PCR for an acute myocardial infarction were excluded.
The primary endpoint, a composite of death and myocardial infarction at 1 year, occurred
in 33 patients (12.5%).
Before PCR, mean HGF level was 2582±2322 pg/mL and mean VEGF level was
604±471 pg/mL. By univariate analysis, baseline HGF and VEGF levels were signifi-
cantly higher in patients reaching a clinical endpoint (3463±2671 pg/mL vs 2455±2264
pg/mL, p=0.004 and 895+774 pg/mL vs 562+395 pg/mL, p=0.007; respectively).
For multivariate analysis, the population was dichotomized in 2 groups : low versus high
levels according to the median value. By multivariate analysis 4 predictors of clinical
events were identified: Diabetes mellitus (Hazard ratio (HR) = 2.82, 95% confidence
interval (CI) = 1.42-5.62; p=0.003), “high” HGF levels (HR = 2.93, 95% CI = 1.32-6.54;
p=0.008), “high” VEGF level (HR = 2.37, 95% CI = 1.12-5.00; p=0.02) and CRP > 4 mg/L
(HR = 2.39, 95% CI = 1.04-5.49; p=0.04).
When HGF and VEGF data were combined, the HR for patients with combined high HGF
and High VEGF levels was 4.00 (95% CI: 1.97-7.87; p=0.0001).
Conclusion : Our results demonstrate that in patients referred for PCR, high serum levels
of VEGF and HGF are associated with an increased rate of clinical major events during
the first year of follow up. The predictive value of VEGF and HGF levels is mutually addi-
tive and is independent of other known clinical and biological risk factors.
1103-166 Brachial Artery Intima-Media Thickness Is Closely 
Related to Long-Term Cardiovascular Events
Alois Suessenbacher, Matthias Frick, Hannes Alber, Otmar Pachinger, Franz Weidinger, 
University of Innsbruck, Innsbruck, Austria
Background: We have recently demonstrated that brachial artery intima-media thick-
ness (BA-IMT) is associated with cardiovascular risk factors and coronary artery disease
(CAD). The prognostic value of BA-IMT has not been investigated. The aim of this study
was to determine the relation of BA-IMT with late cardiovascular events in patients admit-
ted for stable angina.
Methods: In 294 patients (age 54±10 years) undergoing coronary angiography (CA),
BA-IMT was measured using high-resolution ultrasound (13 MHz) by an observer blinded
to CA diagnosis. 211 patients (72%) had CAD (>30% diameter stenosis in >1 major ves-
sel) and 83 patients (28%) had smooth coronaries (non-CAD). All patients underwent
brachial artery ultrasound examination for measurements of IMT of the far wall. Patients
were divided into 2 groups: BA-IMT above the median of 0.37mm (group 1) and BA-
IMT<0.37mm (group 2). After a mean follow-up of 38±16 months, cardiovascular events
(hospitalization due to angina pectoris, CA, revascularization, myocardial infarction, car-
diac death) were documented by direct patient contact and confirmed by review of hospi-
tal records.
Results: At baseline age (58±9 vs. 51±9years; <0.001), body mass index (28±4 vs.
26±3kg/m2; p<0.001) and the proportion of CAD-patients (82 vs. 63%; p<0.001) were
greater in group 1, whereas the number of risk factors (1.9±0.9 vs. 1.8±1.0; NS) was
comparable between groups. Cardiovascular events (n=52) were more frequent in group
1 than in group 2 patients (34 vs. 18; p=0.01 in the log-rank test). On multivariate Cox
regression analysis, BA-IMT >0.37mm (odds ratio=1.96; p=0.03), number of risk factors
(odds ratio=1.51; p=0.01) and presence of CAD (odds ratio=3.09; p=0.02) remained sig-
nificantly associated with cardiovascular events.
Conclusion: In patients with stable angina brachial artery-IMT is independently associ-
ated with long-term cardiovascular events. This easily measurable parameter may
become useful in the noninvasive assessment of cardiovascular risk.
Effects of Niacin Extended-Release/Lovastatin in Patients With and Without Metabolic 
Sundrome
No Metabolic Syndrome Metabolic Syndrome
Baseline Week 52
% Change
Baseline Week 52
% Change
LDL-C mean 201 (2.2) -45% (0.9) 192 (1.9) -42% (1.0)
HDL-C mean 52 (0.6) +32% (1.3) 44 +36% (1.6)*
TG median 140 -32% 210
-47%*
Lp(a) median 24 -26% 23 -22%
Baseline values are in mg/dL (+ standard error for mean values).  Mean % change (+ 
standard error) for LDL-C and HDL-C.  Median % change for TG and Lp(a).  p<0.05 
versus patients without MS.
Effects of Niacin Extended-Release on Lipids in Patients With and Without CKD
No CKD CKD
Baseline Week 48
% Change
Baseline Week 48
% Change
LDL-C mean 191 (1.7) -17% (1.1) 200 (2.8)
-23%* (1.1)
HDL-C mean 43 (0.5) +23% (1.4) 49 (0.75) +29%* (2.1)
TG median 160 -31% 155 -36%
Lp(a) median 21 -36% 32 -33%
LDL-C = low-density lipoprotein cholesterol.  Baseline values are in mg/dL (+ standard 
error for mean values).  Mean % change (+ standard error) for LDL-C and HDL-C.  
Median % change for TG and Lp(a).  *p<0.05 versus patients without CKD.
